注射用磷罗拉匹坦帕洛诺司琼 | China Drugs ListFosrolapitant and palonosetron hydrochloride for injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 福建盛迪医药有限公司Fujian Shengdi Pharmaceutical Co., Ltd.
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 用于预防成人高度致吐性化疗（HEC）引起的急性和迟发性恶心、呕吐；说明书推荐在相应化疗周期配合地塞米松使用。To prevent acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy (HEC) in adults. The label recommends use with dexamethasone in the relevant chemotherapy cycle.
- 适应症来源与口径
- 来源日期： 2026-07-27, 2026-10-23. 生产商面向中国大陆的药品说明书。 证据核查日期：2026年10月23日。Source date(s): 2026-07-27, 2026-10-23. Manufacturer prescribing information for Mainland China. Evidence review: 23 October 2026.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。 生产商原始页面图像已按顺序保存。Complete official prescribing information obtained. Mainland China label. Original manufacturer page images have been preserved in order.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限预防成人高度致吐性化疗(HEC)引起的急性和迟发性恶心和呕吐。Restricted to prevention of acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy in adults.
- 医保期限
- 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
来源
- https://www.cde.org.cn/main/news/viewInfoCommon/b93aba16ec47467317057dca4aac8437
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.hengrui.com/product/innovativeMedicine.html?type=1
- https://www.hengrui.com/uploads/2026091004350632fa3771-171f-425e-81e1-2b54580fc3a8/1.jpg
